A new study of TQB6411 for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests an experimental drug, TQB6411, for people with esophageal cancer that has come back or spread. It may be an option if previous treatments, including immunotherapy and chemotherapy, have stopped working or caused side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with esophageal cancer that has returned or spread.
- You have tried a PD-1/PD-L1 inhibitor (like pembrolizumab or nivolumab) and platinum-based chemotherapy, and they didn't work or you couldn't tolerate them.
- You have at least one tumor that can be measured on a scan.
- Your overall health is reasonably good (ECOG 0-1), and your doctor expects you to live at least 3 months.
- Your blood tests show adequate liver, kidney, and bone marrow function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called TQB6426 for people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein called GPC3 found on some tumor cells. The goal is to see if the drug is safe and effective.
This trial tests a new combination of drugs (TQB2102, benmelstobart, and pembrolizumab) with or without chemotherapy for people with HER2-positive gastroesophageal cancer that cannot be removed by surgery or has spread. It aims to see if this combination is more effective than current treatments.
This trial tests a new drug, TQB2102, for people with advanced bile duct cancer that has HER2 protein markers. It aims to see if the drug can help when previous treatments haven't worked.
This trial tests a new drug, TQB6411, for people with advanced cancers that have not responded to standard treatments. It aims to see if the drug is safe and effective for different tumor types.
This trial tests a new drug called TQB6411 for people with lung cancer that can be measured by scans. The drug is given by injection, and the study will see if it is safe and if it helps shrink or control the cancer.
This trial tests an investigational drug called TQB2101 for people with advanced solid tumors that have not responded to standard treatments. The study aims to see how safe the drug is and how the body processes it, and it may offer a new option for those with few alternatives.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.